Memantine’s NMDA receptor antagonism and donepezil’s acetylcholinesterase inhibition provide established symptomatic benefit for AD patients, though neither compound demonstrates disease-modifying effects on underlying pathology. Here, ACHE is linked to Alzheimer disease.